Sprint Bioscience AB (publ)

Stockholm Stock Exchange SPRINT.ST

Sprint Bioscience AB (publ) EBITDA Margin for the year ending December 31, 2023: -4.12%

Sprint Bioscience AB (publ) EBITDA Margin is -4.12% for the year ending December 31, 2023, a 99.99% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Sprint Bioscience AB (publ) EBITDA Margin for the year ending December 31, 2022 was -72,286.75%, a -103,532.75% change year over year.
Sprint Bioscience AB (publ) EBITDA Margin for the year ending December 31, 2021 was -69.75%, a 69.05% change year over year.
Sprint Bioscience AB (publ) EBITDA Margin for the year ending December 31, 2020 was -225.37%, a -285.95% change year over year.
Sprint Bioscience AB (publ) EBITDA Margin for the year ending December 31, 2019 was -58.39%, a 66.28% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Stockholm Stock Exchange: SPRINT.ST

Sprint Bioscience AB (publ)

CEO	Mr. Johan Emilsson
IPO Date	Nov. 7, 2014
Location	Sweden
Headquarters	Novum
Employees	36
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

Key trends

Past 5 years